A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study
Abstract Background The Dallas Metastatic Cancer Study is a clinical database established to examine local trends associated with the diagnosis and treatment of de novo metastatic breast cancer and identify factors for further evaluation. Clinical characteristics of patients with de novo metastatic...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-08-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-025-01011-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234577487298560 |
|---|---|
| author | Hannah L. Chang Meng Cao Mir Lim Anna Moscowitz Ang Gao Ariana Weiss Ariel Brown Danielle Spanbauer Giselle Uwera Jaeyoung Oh Jonathan Ladner Nathaniel Wu Priscilla Okanlawon Reynaldo Olivo Ruchita Iyer Yemariamwork Engidaw Sangeetha M. Reddy Heather L. McArthur Lily Xu Sakshi Mohta Julia Maues Christine Hodgdon Luis Chinea Katherine Lei Shao-Po Huang Rani Bansal Isaac S. Chan |
| author_facet | Hannah L. Chang Meng Cao Mir Lim Anna Moscowitz Ang Gao Ariana Weiss Ariel Brown Danielle Spanbauer Giselle Uwera Jaeyoung Oh Jonathan Ladner Nathaniel Wu Priscilla Okanlawon Reynaldo Olivo Ruchita Iyer Yemariamwork Engidaw Sangeetha M. Reddy Heather L. McArthur Lily Xu Sakshi Mohta Julia Maues Christine Hodgdon Luis Chinea Katherine Lei Shao-Po Huang Rani Bansal Isaac S. Chan |
| author_sort | Hannah L. Chang |
| collection | DOAJ |
| description | Abstract Background The Dallas Metastatic Cancer Study is a clinical database established to examine local trends associated with the diagnosis and treatment of de novo metastatic breast cancer and identify factors for further evaluation. Clinical characteristics of patients with de novo metastatic breast cancer are often underreported in the literature. Methods We report data from 2010 to 2021 for patients with de novo metastatic breast cancer along with the impact of clinical variables such as age, BMI, race and ethnicity, insurance status, hypertension, diabetes, and site of metastasis with survival analysis with respect to subtype. Results Black race (HR 2.07, 95% CI 1.56–2.74), public insurance (HR 1.64, 95% CI 1.23–2.18), no insurance (HR 1.69, 95% CI 1.24–2.31), hypertension (HR 1.50, 95% CI 1.18–1.91), diabetes (HR 1.69, 95% CI 1.24–2.31), and visceral metastases including brain (HR 1.68, 95% CI 1.20–2.36), liver (HR 1.80, 95% CI 1.40–2.30), and lung (HR 1.50, 95% CI 1.17–1.92) were associated with increased mortality and remained significant when controlled for subtype. In the multivariate analysis, diabetes (HR 1.74, 95% CI 1.22–2.49) and presence of liver metastases (HR 1.97, 95% CI 1.43–2.49) remained independently associated with decreased overall survival regardless of subtype and other variables. Patients diagnosed at 40 and younger were less likely to have hypertension and diabetes, more likely to be Hispanic, and showed distinct subtype distributions compared to those diagnosed at older ages. Conclusions Future work will focus on these associations at the patient level to identify targets for intervention. |
| format | Article |
| id | doaj-art-e9d511dcfc214cb78c1cb6def11e03fa |
| institution | Kabale University |
| issn | 2730-664X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Communications Medicine |
| spelling | doaj-art-e9d511dcfc214cb78c1cb6def11e03fa2025-08-20T04:03:06ZengNature PortfolioCommunications Medicine2730-664X2025-08-01511710.1038/s43856-025-01011-5A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer StudyHannah L. Chang0Meng Cao1Mir Lim2Anna Moscowitz3Ang Gao4Ariana Weiss5Ariel Brown6Danielle Spanbauer7Giselle Uwera8Jaeyoung Oh9Jonathan Ladner10Nathaniel Wu11Priscilla Okanlawon12Reynaldo Olivo13Ruchita Iyer14Yemariamwork Engidaw15Sangeetha M. Reddy16Heather L. McArthur17Lily Xu18Sakshi Mohta19Julia Maues20Christine Hodgdon21Luis Chinea22Katherine Lei23Shao-Po Huang24Rani Bansal25Isaac S. Chan26Department of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterPeter O’Donnell Jr. School of Public Health, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterGRASPGRASPDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterDepartment of Medicine, Duke UniversityDepartment of Internal Medicine, Division of Hematology and Oncology, University of Texas Southwestern Medical CenterAbstract Background The Dallas Metastatic Cancer Study is a clinical database established to examine local trends associated with the diagnosis and treatment of de novo metastatic breast cancer and identify factors for further evaluation. Clinical characteristics of patients with de novo metastatic breast cancer are often underreported in the literature. Methods We report data from 2010 to 2021 for patients with de novo metastatic breast cancer along with the impact of clinical variables such as age, BMI, race and ethnicity, insurance status, hypertension, diabetes, and site of metastasis with survival analysis with respect to subtype. Results Black race (HR 2.07, 95% CI 1.56–2.74), public insurance (HR 1.64, 95% CI 1.23–2.18), no insurance (HR 1.69, 95% CI 1.24–2.31), hypertension (HR 1.50, 95% CI 1.18–1.91), diabetes (HR 1.69, 95% CI 1.24–2.31), and visceral metastases including brain (HR 1.68, 95% CI 1.20–2.36), liver (HR 1.80, 95% CI 1.40–2.30), and lung (HR 1.50, 95% CI 1.17–1.92) were associated with increased mortality and remained significant when controlled for subtype. In the multivariate analysis, diabetes (HR 1.74, 95% CI 1.22–2.49) and presence of liver metastases (HR 1.97, 95% CI 1.43–2.49) remained independently associated with decreased overall survival regardless of subtype and other variables. Patients diagnosed at 40 and younger were less likely to have hypertension and diabetes, more likely to be Hispanic, and showed distinct subtype distributions compared to those diagnosed at older ages. Conclusions Future work will focus on these associations at the patient level to identify targets for intervention.https://doi.org/10.1038/s43856-025-01011-5 |
| spellingShingle | Hannah L. Chang Meng Cao Mir Lim Anna Moscowitz Ang Gao Ariana Weiss Ariel Brown Danielle Spanbauer Giselle Uwera Jaeyoung Oh Jonathan Ladner Nathaniel Wu Priscilla Okanlawon Reynaldo Olivo Ruchita Iyer Yemariamwork Engidaw Sangeetha M. Reddy Heather L. McArthur Lily Xu Sakshi Mohta Julia Maues Christine Hodgdon Luis Chinea Katherine Lei Shao-Po Huang Rani Bansal Isaac S. Chan A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study Communications Medicine |
| title | A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study |
| title_full | A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study |
| title_fullStr | A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study |
| title_full_unstemmed | A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study |
| title_short | A comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the Dallas Metastatic Cancer Study |
| title_sort | comprehensive evaluation of de novo metastatic breast cancer trends by subtype from the dallas metastatic cancer study |
| url | https://doi.org/10.1038/s43856-025-01011-5 |
| work_keys_str_mv | AT hannahlchang acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT mengcao acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT mirlim acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT annamoscowitz acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT anggao acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT arianaweiss acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT arielbrown acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT daniellespanbauer acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT giselleuwera acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT jaeyoungoh acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT jonathanladner acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT nathanielwu acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT priscillaokanlawon acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT reynaldoolivo acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT ruchitaiyer acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT yemariamworkengidaw acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT sangeethamreddy acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT heatherlmcarthur acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT lilyxu acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT sakshimohta acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT juliamaues acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT christinehodgdon acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT luischinea acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT katherinelei acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT shaopohuang acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT ranibansal acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT isaacschan acomprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT hannahlchang comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT mengcao comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT mirlim comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT annamoscowitz comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT anggao comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT arianaweiss comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT arielbrown comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT daniellespanbauer comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT giselleuwera comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT jaeyoungoh comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT jonathanladner comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT nathanielwu comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT priscillaokanlawon comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT reynaldoolivo comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT ruchitaiyer comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT yemariamworkengidaw comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT sangeethamreddy comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT heatherlmcarthur comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT lilyxu comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT sakshimohta comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT juliamaues comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT christinehodgdon comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT luischinea comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT katherinelei comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT shaopohuang comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT ranibansal comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy AT isaacschan comprehensiveevaluationofdenovometastaticbreastcancertrendsbysubtypefromthedallasmetastaticcancerstudy |